The Radiological Image of the Spread Gastric Cancer to the Nervous System in Patient with Presence of HER-2 Overexpression

Background: HER-2/neu is a predictive biomarker for treatment of gastric cancer using trastuzumab in combination with chemotherapy. This study aimed to evaluate the status of HER-2/neu gene amplification using fluorescence in situ hybridization (FISH) in gastric cancer. Patients and methods: thirty six gastric cancer patients were assessed HER-2/neu gene amplification by FISH using PathVysionTM HER-2 DNA Probe kit (including HER-2/neu probe and CEP-17 probe) with biopsy and surgical specimens. Results: The HER-2/neu gene amplification was observed in three cases (8.3%), the HER-2/neu gene amplification rate in Lauren’s intestinal-type and diffuse-type were 11.8% and 5.2%, respectively. Conclusion: We applied successfully FISH technique with gastric cancer tissue samples. This technique could be performed as routine test in gastric cancer in order to select patients that benefit from trastuzumab in combination with chemotherapy.

Download Full-text

HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer

Digestive Diseases and Sciences ◽

10.1007/s10620-005-9057-1 ◽

2006 ◽

Vol 51 (8) ◽

pp. 1371-1379 ◽

Cited By ~ 184

Author(s):

Dong Il Park ◽

Jung Won Yun ◽

Jung Ho Park ◽

Suk Joong Oh ◽

Hong Joo Kim ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Independent Prognostic Factor ◽

Her 2

Download Full-text

HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients

The Scientific World JOURNAL ◽

10.1100/2012/941259 ◽

2012 ◽

Vol 2012 ◽

pp. 1-6 ◽

Cited By ~ 23

Author(s):

Agnieszka Halon ◽

Piotr Donizy ◽

Przemyslaw Biecek ◽

Julia Rudno-Rudzinska ◽

Wojciech Kielan ◽

...

Keyword(s):

Gastric Cancer ◽

Test Score ◽

Prognostic Significance ◽

Clinicopathological Parameters ◽

Prognostic Impact ◽

Curative Surgery ◽

Regional Lymph Nodes ◽

Poorly Differentiated ◽

Her 2 ◽

Gastric Cancer Patients

The role of HER-2 expression as a prognostic factor in gastric cancer (GC) is still controversial. The aim of the study was to asses HER-2 status, its correlations with clinicopathological parameters, and prognostic impact in GC patients. Tumor samples were collected from 78 patients who had undergone curative surgery. In order to evaluate the intensity of immunohistochemical (IHC) reactions two scales were applied: the immunoreactive score according to Remmele modified by the authors and standardised Hercep test score modified for GC by Hofmann et al. The HER-2 overexpression was detected by IHC in 23 (29.5%) tumors in Hercep test (score 2+/3+) and in 24 (30.7%) in IRS scale (IRS 4–12). The overexpression of HER-2 was associated with poorly differentiated tumors, but this correlation was not significant (P=0.064). No relationship was found between HER-2 expression and primary tumor size and degree of spread to regional lymph nodes. Both univariate and multivariate analyses revealed that TNM stage and patient’s age were the crucial negative prognostic factors. No correlation was observed between patient survival and expression of HER-2 estimated using both scales. This research did not confirm HER-2 expression (evaluated with immunohistochemistry) value as a prognostic tool in GC.

Download Full-text

The expression and clinical significance of PDCD4 and Her-2 in human gastric cancer

European Journal of Inflammation ◽

10.1177/2058739219828236 ◽

2019 ◽

Vol 17 ◽

pp. 205873921982823

Author(s):

Yuelou Yang ◽

Xiangjun Jiang ◽

Dong Li ◽

Feiyan Wang ◽

Qun Yang ◽

...

Keyword(s):

Gastric Cancer ◽

Protein Expression ◽

Western Blot ◽

Clinical Significance ◽

Normal Mucosa ◽

Normal Tissues ◽

Positive Rate ◽

Her 2 ◽

Cancer Tissues ◽

Pdcd4 Protein

To investigate the correlation and clinical significance between programmed cell death factor 4 (PDCD4) and epidermal growth factor receptor 2 (Her-2) expressions and clinicopathological parameters in patients with gastric cancer, a total of 65 cases of gastric cancer and the corresponding normal mucosa with PDCD4 and Her-2 protein expressions were detected by SP immunohistochemical staining, and 50 cases of gastric cancer and the corresponding normal mucosa with PDCD4 and Her-2 protein expression quantities were detected by Western blot, in order to analyze the relationship between the positive expressions of PDCD4 and Her-2 protein and the clinicopathological features of patients with gastric cancer. The results showed that the positive rate of PDCD4 protein expression in gastric cancer tissues was 7.7%, which was significantly lower than that in the corresponding normal tissues, that is, 77.5% ( P < 0.05); the positive rate of Her-2 expression was 41.5%, which was significantly higher than that of the corresponding normal tissues, which is 2.5% ( P < 0.05). The Western blot test showed that the expression of PDCD4 protein in gastric cancer was 0.3105 ± 0.0073, which was significantly lower than that in the corresponding normal tissues, that is, 0.9428 ± 0.0127 ( P < 0.05); the expression level of Her-2 protein in gastric cancer tissues was 0.9428 ± 0.0127, which was significantly higher than that of the corresponding normal mucosa, which is 0.2054 ± 0.0264 ( P < 0.05). The positive expressions of PDCD4 (5/65) and Her-2 (27/65) were significantly correlated with the differentiation degrees and TNM stages of gastric cancer ( P < 0.05). However, no significant correlation can be observed from Table 2 ( P > 0.05), regarding sex, age, tumor size, and lymph node metastasis. Our research claimed that PDCD4 and Her-2 may play an important role in the invasion and metastasis of gastric cancer, which has a negative correlation with biological behaviors of gastric cancer. The low expression of PDCD4 and the high expression of Her-2 in gastric cancer may promote the occurrence and progression of cancer. The PDCD4 and Her-2 test can be used as an index to evaluate the malignant biological behaviors of gastric cancer and prognosis, and provide a theoretical basis for targeted therapy.

Download Full-text

Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens

Cell Biochemistry and Biophysics ◽

10.1007/s12013-011-9286-1 ◽

2011 ◽

Vol 62 (1) ◽

pp. 221-228 ◽

Cited By ~ 68

Author(s):

Jiyuan Yang ◽

Hesheng Luo ◽

Yan Li ◽

Junchuan Li ◽

Zhiqiang Cai ◽

...

Keyword(s):

Gastric Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Diagnostic Tests ◽

Growth Factor Receptor ◽

Intratumoral Heterogeneity ◽

Human Epidermal Growth Factor ◽

Her 2 ◽

Epidermal Growth

Download Full-text

Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer

Frontiers in Oncology ◽

10.3389/fonc.2020.580045 ◽

2021 ◽

Vol 10 ◽

Author(s):

Huifang Lv ◽

Junling Zhang ◽

Keran Sun ◽

Caiyun Nie ◽

Beibei Chen ◽

...

Keyword(s):

Gastric Cancer ◽

T Cells ◽

Checkpoint Inhibitors ◽

Growth Factor Receptor ◽

Progression Free Survival ◽

Underlying Mechanism ◽

Tumor Location ◽

The Cancer Genome Atlas ◽

Prognostic Indicators ◽

Her 2

BackgroundPD-L1 and HER-2 are routine biomarkers for gastric cancer (GC). However, little research has been done to investigate the correlation among PD-L1, HER-2, immune microenvironment, and clinical features in GC.MethodsBetween January 2013 and May 2020, a total of 120 GC patients treated with chemotherapy were admitted to Henan Tumor Hospital. We retrospectively identified PD-L1, HER-2 level before chemotherapy and abstracted clinicopathologic features and treatment outcomes. Univariate and multivariate survival analyses were performed to assess the relationship between PD-L1/HER-2 levels and progression-free survival (PFS). The mRNA and tumor microenvironment of 343 patients with GC from The Cancer Genome Atlas (TCGA) were used to explore the underlying mechanism.ResultsWe retrospectively analyzed 120 patients with gastric cancer, including 17 patients with HER-2 positive and 103 patients with HER-2 negative GC. The results showed that the expression of PD-L1 was closely correlated with HER-2 (P = 0.015). Patients with PD-L1/HER-2 positive obtained lower PFS compared to PD-L1/HER-2 negative (mPFS: 6.4 vs. 11.1 months, P = 0.014, mPFS: 5.3 vs. 11.1 months, P = 0.002, respectively), and the PD-L1 negative and HER-2 negative had the best PFS than other groups (P = 0.0008). In a multivariate model, PD-L1 status, HER-2 status, tumor location, and tumor differentiation remained independent prognostic indicators for PFS (P < 0.05). The results of database further analysis showed that the proportion of PD-L1+/CD8A+ in HER-2 negative patients was higher than that in HER-2 positive patients (37.6 vs 20.3%), while PD-L1−/CD8A− was significantly higher in HER-2 positive patients than HER-2 negative patients (57.8 vs. 28.8%). In addition, it showed that not only CD4+T cells, macrophages, and CD8+T cells, but also the associated inflammatory pathways such as IFN-γ/STAT1 were associated with HER-2.ConclusionHER-2 status could predict the efficacy of immune checkpoint inhibitors, and HER-2 status combined with PD-L1 level could predict the prognosis of GC patients.

Download Full-text